| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Memorial Sloan-Kettering Cancer Center |
| Information provided by: | Memorial Sloan-Kettering Cancer Center |
| ClinicalTrials.gov Identifier: | NCT00608452 |
Purpose
You may have a type of cancer associated with "antineuronal antibodies" in your blood.
Antibodies are substances made by the immune system. They are used by the body to fight infections and other diseases. Antineuronal antibodies are antibodies that react with nerve cells but they also react with some tumors. We believe that the immune system makes these antibodies to fight the cancer. In some patients with these antibodies, the tumor is smaller than in patients who have no antibodies. Sometimes, with a very strong antibody test, patients may develop neurologic problems such as weakness, numbness or memory loss. One purpose of this study is to determine if a patient with cancer and a positive antineuronal antibody blood test has a smaller tumor and responds better to treatment than a patient with cancer and a negative test. Another purpose of this study is to determine whether patients with a positive antibody test develop neurologic problems such as weakness, numbness or memory loss.
We will measure your blood for several different kinds of antibodies in addition to antineuronal antibodies to determine if the presence of antibodies predicts "prognosis", i.e. smaller tumor and better response to treatment, or predicts the development of neurologic problems.
No tissue samples are required for this study. However, if tissue or sputum is obtained by your oncologist for diagnostic purposes, we will ask your doctors or the pathology department to provide us with samples of these specimens. This will not involve any additional surgery or discomfort to you.
| Condition | Intervention |
|
Lung Cancer Ovarian Cancer Breast Cancer Hodgkin's Disease Neuroblastoma |
Other: Symptom Assessment Scale |
| Genetics Home Reference related topics: | breast cancer |
| MedlinePlus related topics: | Breast Cancer Cancer Hodgkin's Disease Lung Cancer Neuroblastoma Ovarian Cancer |
| Study Type: | Observational |
| Study Design: | Case-Only, Prospective |
| Official Title: | A Prospective Study of The Prevalence and Significance of Paraneoplastic Autoantibodies in Small Cell Lung Cancer and Cancer of The Breast, Ovary, Hodgkin's Disease, Neuroblastoma and Other Cancers |
blood samples for autoantibody determinations and HLA typing
| Estimated Enrollment: | 180 |
| Study Start Date: | July 1995 |
| Estimated Study Completion Date: | July 2009 |
| Estimated Primary Completion Date: | July 2009 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
| 1 |
Other: Symptom Assessment Scale
|
 |
Show Detailed Description |
Eligibility
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Patients with previous cancers or concurrent cancers. Patient has or may have, newly-diagnosed or recurrent SCLC, or mixed small cell/non small cell lung cancer, or neuroblastoma, or ovarian or breast cancer, or Hodgkin's disease in all cases confirmed by pathological review.
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| United States, New York | |||||
| Memorial Sloan Kettering Cancer Center | |||||
| New York, New York, United States, 10065 | |||||
| Memorial Sloan-Kettering Cancer Center |
| Principal Investigator: | Jerome Posner, MD | Memorial Sloan-Kettering Cancer Center |
More Information
Memorial Sloan-Kettering Cancer Center
|
| Responsible Party: | Memorial Sloan-Kettering Cancer Center ( Posner, Jerome, M /Principal Investigator ) |
| Study ID Numbers: | 95-046 |
| First Received: | January 23, 2008 |
| Last Updated: | January 23, 2008 |
| ClinicalTrials.gov Identifier: | NCT00608452 |
| Health Authority: | United States: Institutional Review Board |
|
|
|
|
|
|
